ArticleCancer science2020

Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.

Kazuki Kuroshima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.